OOIR: Observatory of International Research

Papers

(The TQCC of Hematology-American Society of Hematology Education Program is 11. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Managing toxicities of Bruton tyrosine kinase inhibitors	92
Therapeutic development and current uses of BCL-2 inhibition	74
Platelet transfusion refractoriness: how do I diagnose and manage?	49
Managing toxicities of phosphatidylinositol-3-kinase (PI3K) inhibitors	45
Preventing infections in children and adults with asplenia	44
Monoclonal gammopathies of clinical significance	42
Gene therapy for hemophilia	40
Updates in infection risk and management in acute leukemia	40
Bispecifics, trispecifics, and other novel immune treatments in myeloma	40
Therapy for lower-risk MDS	34
Management of AL amyloidosis in 2020	34
Updates in chronic graft-versus-host disease	34
Dyskeratosis congenita and telomere biology disorders	34
Next-generation cell therapies: the emerging role of CAR-NK cells	32
Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes	30
Inferior vena cava filters: a framework for evidence-based use	29
Does ABO and RhD matching matter for platelet transfusion?	28
Increasing access to allotransplants in the United States: the impact of race, geography, and socioeconomics	27
“TEG talk”: expanding clinical roles for thromboelastography and rotational thromboelastometry	26
Advances in the management of α-thalassemia major: reasons to be optimistic	26
Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia	26
Future of CAR T cells in multiple myeloma	25
Outpatient transfusions for myelodysplastic syndromes	24
Management of Waldenström macroglobulinemia in 2020	24
Evidence-Based Minireview: Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review	24

Modern management of Fanconi anemia	24
Approach to the patient with suspected hypereosinophilic syndrome	24
Have we reached a molecular era in myelodysplastic syndromes?	23
Prevention and treatment of postpartum hemorrhage: focus on hematological aspects of management	23
Combining antiplatelet and anticoagulant therapy in cardiovascular disease	22
Allogeneic hematopoietic cell transplantation for older patients	22
Practical approach to monitoring and prevention of infectious complications associated with systemic corticosteroids, antimetabolites, cyclosporine, and cyclophosphamide in nonmalignant hematologic di	22
What to use to treat AML: the role of emerging therapies	21
Antibodies and bispecifics for multiple myeloma: effective effector therapy	21
High-risk multiple myeloma: how to treat at diagnosis and relapse?	20
Indications for transfusion in the management of sickle cell disease	20
Women and bleeding disorders: diagnostic challenges	20
Diagnosis and management of iron deficiency in chronic inflammatory conditions (CIC): is too little iron making your patient sick?	20
Gene therapy for sickle cell disease: where we are now?	20
Optimizing the management of chronic pain in sickle cell disease	19
Identifying potential germline variants from sequencing hematopoietic malignancies	19
Epidemiology and treatment of priapism in sickle cell disease	19
Hereditary hemorrhagic telangiectasia (HHT): a practical guide to management	18
Special pre- and posttransplant considerations in inherited bone marrow failure and hematopoietic malignancy predisposition syndromes	18
How to avoid the problem of erythrocyte alloimmunization in sickle cell disease	18
First-generation vs second-generation tyrosine kinase inhibitors: which is best at diagnosis of chronic phase chronic myeloid leukemia?	18
Management of heavy menstrual bleeding on anticoagulation	18
Mechanisms of somatic transformation in inherited bone marrow failure syndromes	17
Treatment of immune-mediated cytopenias in patients with primary immunodeficiencies and immune regulatory disorders (PIRDs)	17
Does aspirin prevent venous thromboembolism?	17
How do we sequence therapy for marginal zone lymphomas?	17
Available and emerging therapies for bona fide advanced systemic mastocytosis and primary eosinophilic neoplasms	17
Increasing access to allogeneic hematopoietic cell transplant: an international perspective	17
Management of toxicities associated with targeted therapies for acute myeloid leukemia: when to push through and when to stop	17
Blast and accelerated phase CML: room for improvement	16
Cellular therapy for multiple myeloma: what's now and what's next	16
How to recognize and manage COVID-19-associated coagulopathy	16
Double-hit lymphoma: optimizing therapy	16
Hematology 2022—what is complete HLA match in 2022?	15
Treatment of Richter's syndrome	15
Practice patterns and outcomes for adults with acute myeloid leukemia receiving care in community vs academic settings	15
Hemophilia gene therapy: ushering in a new treatment paradigm?	15
Evidence-Based Minireview: Abnormal uterine bleeding in users of rivaroxaban and apixaban	15
When does a PNH clone have clinical significance?	15
Transformed lymphoma: what should I do now?	15
Chemotherapy-free frontline therapy for CLL: is it worth it?	15
Extrahematopoietic manifestations of the short telomere syndromes	14
How to manage CML patients with comorbidities	14
Challenges in chronic transfusion for patients with thalassemia	14
β-Thalassemia: evolving treatment options beyond transfusion and iron chelation	14
In 2022, which is preferred: haploidentical or cord transplant?	14
Evaluating patients with autoimmune hemolytic anemia in the transfusion service and immunohematology reference laboratory: pretransfusion testing challenges and best transfusion-management strategies	13
Diamond-Blackfan anemia	13
Molecular prognostication in Ph-negative MPNs in 2022	13
Genomics of MPN progression	13

Updates on the diagnosis and management of the most common hereditary porphyrias: AIP and EPP	13
Achieving MRD negativity in AML: how important is this and how do we get there?	13
Relapsed ALL: CAR T vs transplant vs novel therapies	13
Rituximab and eculizumab when treating nonmalignant hematologic disorders: infection risk, immunization recommendations, and antimicrobial prophylaxis needs	13
Direct oral anticoagulant (DOAC) interference in hemostasis assays	13
Global look at nutritional and functional iron deficiency in infancy	13
Sequencing multiple myeloma therapies with and after antibody therapies	12
Sequencing therapy in relapsed DLBCL	12
Heparin-induced thrombocytopenia and cardiovascular surgery	12
How to evaluate and treat the spectrum of TMA syndromes in pregnancy	12
Factor-mimetic and rebalancing therapies in hemophilia A and B: the end of factor concentrates?	12
Inherited microcytic anemias	12
COVID-19 and thrombosis: searching for evidence	12
Unexplained arterial thrombosis: approach to diagnosis and treatment	11
Warm autoimmune hemolytic anemia and the best treatment strategies	11
Strategies for introducing palliative care in the management of relapsed or refractory aggressive lymphomas	11
How to evaluate for immunodeficiency in patients with autoimmune cytopenias: laboratory evaluation for the diagnosis of inborn errors of immunity associated with immune dysregulation	11
Advances in MGUS diagnosis, risk stratification, and management: introducing myeloma-defining genomic events	11
Social aspects of chronic transfusions: addressing social determinants of health, health literacy, and quality of life	11
CHIP: is clonal hematopoiesis a surrogate for aging and other disease?	11
Allogeneic hematopoietic stem cell transplantation in adults with primary immunodeficiency	11